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Abstract Pax4 is a paired-box transcription factor that plays
an important role in the development of pancreatic L-cells. Two
Pax4 cDNAs were isolated from a rat insulinoma library. One
contained the full-length sequence of Pax4. The other, termed
Pax4c, was identical to Pax4 but lacked the sequences encoding
117 amino acids at the COOH-terminus. Pax4 was found to
inhibit the human insulin promoter through a sequence element,
the C2 box, located at 3253 to 3244, and the islet amyloid
polypeptide promoter through a sequence element located
downstream of 3138. The inhibitory activity of Pax4 was
mapped to separate regions of the protein between amino acids
2^230 and 231^349.
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1. Introduction
The pax gene family encodes highly conserved DNA-bind-
ing transcription factors that control the expression of genes
during embryogenesis [1,2]. Members of the family are all
characterised by the presence of a DNA-binding motif, known
as the paired domain, with some members of the family also
containing a partial or full homeodomain [3]. Currently nine
members of the family have been identi¢ed in mammalian
genomes. These have been classi¢ed into four subgroups:
Pax1/9, Pax2/5/8, Pax3/7 and Pax4/6. Pax4 and Pax6 are
both involved in pancreatic islet development and are essential
for the di¡erentiation and maturation of pancreatic endocrine
cells. Pax4 gene expression is essential for the di¡erentiation
of L-cells and Pax4-de¢cient mice lack functional L- and N-
cells [4]. In contrast to Pax4, Pax6 gene expression is essential
for the di¡erentiation of K-cells and Pax6 knockout mice lack
islet K-cells [5].
Although it is known that Pax4 is essential for the di¡er-
entiation of L-cells, very little is known about the speci¢c
targets of Pax4 within the L-cells of the islets of Langerhans.
In the present study we report the cloning of a full-length rat
Pax4 cDNA and a shorter isoform, Pax4c, from a rat insuli-
noma library and investigate the role of Pax4 and Pax4c in
controlling insulin and islet amyloid polypeptide (IAPP) pro-
moter activity in L-cells.
2. Materials and methods
2.1. Cloning of rat Pax4 cDNA
A partial mouse Pax4 cDNA [6] (GenBank accession number
Y09584) labelled with [K-32P]dCTP was used to screen a rat insulino-
ma library from CRI-G1 cells. Positive clones were sequenced on both
strands (Alta Bioscience, University of Birmingham, UK).
2.2. In vitro transcription and translation
The pBluescript SK (+/3) phagemid (Stratagene, Amsterdam, The
Netherlands) containing the Pax4 cDNA cloned into the EcoRI and
XhoI restriction sites was linearised with the ApaI restriction enzyme
at the 3P end of the Bluescript polylinker. Transcription reactions were
carried out using T3 RNA polymerase (Boehringer, Mannheim, Ger-
many). The RNA template was translated in a rabbit reticulocyte
lysate following the manufacturer’s speci¢cations (Promega, South-
ampton, UK), and the products analysed by SDS-PAGE.
2.3. Plasmids
The control luciferase reporter construct pGL-LUC is based on the
plasmid pGL2 (Promega), with the thymidine kinase promoter (TKp)
from the herpes simplex virus cloned 5P to the ¢re£y luciferase gene.
The construct pGL-LUC200 varies from this in that it contains 200
base pairs of the human insulin gene promoter between 365 and
3265 upstream of the TKp.
The constructs pBCins-169, pBCins-229, pBCins-258 and pBCins-
341 all contain fragments of the human insulin gene promoter be-
tween 3169 and +112, 3229 and +112, 3258 and +112 and 3341
and +112 cloned upstream of the chloramphenicol acetyl transferase
(CAT) reporter gene [7]. The Pax4 cDNA was cloned into the EcoRI
and XhoI restriction sites of the pCR3 vector (Invitrogen NV, Leek,
The Netherlands) to generate pCR3-PAX4. The Pax4c cDNA was
cloned into the EcoRI and ApaI restriction sites of the pCR3 vector
to generate pCR3-Pax4c.
The pCR3-Pax4/FLAG construct was made by introducing the
FLAG amino acid sequence (Asp Tyr Lys Asp Asp Asp Asp Lys),
between the NH2-terminal methionine and amino acid 2 of Pax4. The
region of Pax4 between 1 and 457 bp was ampli¢ed from pCR3-Pax4
by PCR, using a speci¢c 5P primer containing the sequence for the
FLAG epitope. The ampli¢ed fragment was then cloned into the
pCR3 vector (Invitrogen). The pCR3-Pax4 vector was then digested
with BglII and XhoI to remove the Pax4 fragment between 427 and
1050. The pCR3-Pax4(1^457)/FLAG vector was also digested with
BglII and XhoI, and Pax4(427^1050) was ligated into pCR3-Pax4(1^
457)/FLAG, generating pCR3-Pax4/FLAG.
IAPP gene promoter constructs pTKCAT, pTAC-2798, pTAC-477,
pTAC-391, pTAC-222 and pTAC-138 were constructed as previously
described [13].
The GAL-Pax4 plasmids were constructed by ¢rst amplifying, using
the polymerase chain reaction, the fragment of Pax4 corresponding to
the desired amino acids. The ampli¢ed fragments were digested with
BamHI and XbaI, and cloned in frame with the GAL4 sequences
corresponding to amino acids 1^147 of the GAL4 DNA-binding do-
main in the plasmid pSG424 [8]. The GAL-VP16 construct contains
amino acids 413^490 of VP16 cloned in frame with the GAL4 DNA-
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binding domain in pSG424 [9]. The reporter plasmid pGAL4TKCAT
contains ¢ve copies of the GAL4-binding site cloned upstream of the
herpes virus thymidine kinase promoter in the eukaryotic expression
vector pBL2CAT [10].
2.4. Cell culture
MIN6, a L-cell line derived from transgenic mice expressing the
SV40 large T antigen under the control of the rat insulin gene pro-
moter [11], was grown in DMEM containing 5 mM glucose, supple-
mented with 15% myoclone foetal calf serum (Life Technologies, Pais-
ley, UK). COS-7 and BHK cells were grown in DMEM containing
16 mM glucose, supplemented with 10% (v/v) foetal calf serum (Life
Technologies).
2.5. Transfections
Cells at about 80% con£uence in six-well plates were transfected by
mixing 2 Wg DNA and 24 Wl of a 1 nM lipid suspension containing a
2:1 mixture of dioleoyl-L-K-phosphatidylethanolamine (DOPE), (Sig-
ma, Poole, UK) and dimethyl-dioctadecylammonium bromide
(DDAB), (Fluka) in 1 ml of serum-free Optimem (Life Technologies).
The lipid complexes were allowed to form for 20 min at room temper-
ature before being added to the washed cells. Following 5 h incuba-
tion, 1 ml of complete medium containing 20% foetal calf serum was
added to the cells. After 12 h the medium/DNA complexes were
replaced by complete medium and the cells left for a further 24 h.
The cells were then harvested and the cell pellet resuspended in 100 Wl
of 100 mM KH2PO4 pH 7.8/1 mM dithiothreitol solution and lysed
by freeze/thawing three times. Cell debris was removed by centrifuga-
tion at 13 000 rpm for 1 min.
2.6. Reporter gene assays
For luciferase assay, 30 Wl of cell extract was added to 350 Wl of
bu¡er A pH 7.8 (15 mM MgSO4, 30 mM glycylglycine, 2 mM Na2-
ATP) containing 0.45 mM coenzyme A and 2.56 mM Triton X-100.
To this, 150 Wl of bu¡er G (30 mM glycylglycine) containing 0.5 mM
luciferin (Sigma) was injected and the luminescence read at 560 nm
using a Berthold Luma LB9501. CAT assays were performed using
the Quan T-CAT Assay following the manufacturer’s speci¢cations
(Amersham, Slough, UK). Protein content of the cell extract was
measured using Bio-Rad protein assay reagent.
2.7. Electrophoretic mobility shift assays (EMSA)
For the preparation of nuclear extracts, cells were centrifuged for
30 s in a microcentrifuge and resuspended in 400 Wl of ice-cold bu¡er
containing 10 mM HEPES, pH 7.9, 10 mM KCl, 1 mM dithiothreitol
and 1UProtease Inhibitor Cocktail Solution (Boehringer, Mannheim).
Cells were allowed to swell on ice for 15 min before adding 25 Wl of
10% (v/v) Nonidet P-40. The cells were then vortexed for 15 s and
centrifuged for 30 s in a microcentrifuge. The pellet was resuspended
in 50 Wl of ice-cold bu¡er containing 20 mM HEPES, pH 7.0, 0.4 M
NaCl, 1 mM dithiothreitol, 1UProtease Inhibitor Cocktail Solution
and 5% (v/v) glycerol. After vigorous shaking for 90 min, the nuclear
extract was then centrifuged for 30 s at 4‡C in a microcentrifuge. The
supernatant was collected, divided into small volumes and stored at
370‡C. EMSAs were performed as previously described [12]. Nuclear
extracts (5 Wg of protein) were incubated with radiolabelled probe for
20 min at room temperature in 10 mM Tris^HCl, pH 7.5, 50 mM
KCl, 5 mM dithiothreitol, 1 mM EDTA, and 5% (v/v) glycerol. In
some experiments nuclear extracts were preincubated for 15 min at
4‡C with 3 Wl or 6 Wl of anti-FLAG M5 antibody (Sigma) or pre-
immune serum before addition of the probe. The oligonucleotides
DH1 and C2 used in the EMSAs correspond to the human insulin
gene promoter sequences 5P-AGCTGTGAGCAGGGACAGGTC-
TGGCCACCGGGCCCCTG-3P (located between 3238 and 3275)
and 5P-AGCTGTGAGCAGGGACAGGTCTGGC-3P (located be-
tween 3238 and 3262) respectively.
3. Results
A mouse partial Pax4 cDNA sequence was used as a probe
to screen the rat insulinoma library CRI-G1. The secondary
library screen identi¢ed 14 positives clones, and after sequenc-
ing, one of the clones was found to contain the full-length
sequence of Pax4, which is 1047 bp in length with a single
Fig. 1. In vitro translation of Pax4 and Pax4c. A: Schematic dia-
gram of Pax4 and Pax4c. B: RNA was transcribed from Pax4 and
Pax4c sub-cloned into pBluescript, using T3 RNA polymerase and
translated using rabbit reticulocyte lysate in the presence of
[35S]methionine. The translation products were analysed by SDS-
PAGE. Lane 1 shows the translation process in the absence of
RNA. Lane 2 shows the translation process using 4 Wl of Pax4
RNA. Lane 3 shows the translation process using 4 Wl of Pax4c
RNA.
Fig. 2. E¡ect of Pax4 and Pax4c on pGL-LUC and pGL-LUC200
constructs in MIN6 cells. MIN6 cells were co-transfected with pGL-
LUC and Pax4; with pGL-LUC and Pax4c; with pGL-LUC and
Pax6; with pGL-LUC200 and Pax4; with pGL-Luc200 and Pax4c;
or with pGL-Luc200 and Pax6, as indicated. Luciferase activity is
de¢ned as relative luciferase activity where activity is normalised
against protein concentration. The data are representative of three
separate experiments and show the mean þ S.D. of four separate de-
terminants.
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open reading frame of 349 amino acids (GenBank accession
number AF198155). Two of the clones encoded Pax4c, which
is similar to Pax4 but lacked the 117 amino acids at the
COOH-terminus (GenBank accession number AF198156). A
schematic structure of Pax4 and Pax4c is shown in Fig. 1A.
When the Pax4 and Pax4c genes were transcribed and trans-
lated in vitro they generated single products of approximately
38 kDa and 25 kDa respectively (Fig. 1B). To determine if
Pax4 and Pax4c had a role in regulating the insulin gene the
e¡ect of overexpressing Pax4 and Pax4c on insulin gene tran-
scription was investigated. MIN6 cells were co-transfected
with the control construct pGL-LUC or pGL-LUC200, which
contains a 365 to 3265 fragment of the human insulin gene
promoter and Pax4 or Pax4c. When overexpressed with pGL-
LUC, Pax4 and Pax4c had no e¡ect on transcriptional activ-
ity, but when overexpressed with pGL-LUC200 there was a
decrease in transcriptional activity (Fig. 2). In order to map
the site within the insulin promoter through which Pax4 was
mediating its e¡ect, additional insulin gene promoter con-
structs were used. These comprised deletions of the human
insulin gene promoter cloned upstream of the CAT reporter
gene [7]. Pax4 had no e¡ect on transcriptional activity when
Fig. 3. E¡ect of Pax4 and Pax6 on human insulin gene promoter/CAT constructs. A: MIN6 cells were co-transfected with pBCins-169 and
Pax4; with pBCins-229 and Pax4; or with pBCins-258 and Pax4, as indicated. CAT activity is de¢ned as relative CAT activity where activity is
normalised against protein concentration. The data are representative of three separate experiments and show the mean þ S.D. of four separate
determinants. B: MIN6 cells were co-transfected with pBCins-229 and Pax4; with pBCins-229 and Pax6; with pBCins-258 and Pax4; or with
pBCins-258 and Pax6, as indicated. CAT activity is de¢ned as relative CAT activity where activity is normalised against protein concentration.
The data are representative of three separate experiments and show the mean þ S.D. of four separate determinants.
Fig. 4. EMSA analysis of Pax4 binding to the human insulin gene promoter. Pax4 binding to the insulin gene promoter was analysed by bind-
ing to the oligonucleotide C2 or DH1, from nuclear cell extracts prepared from BHK cells overexpressing Pax4. Competition was performed by
prior incubation of the extract for 20 min with the indicated amount of preimmune rabbit serum (PI) or anti-FLAG antibody.
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overexpressed with pBCins-169 or pBCins-229, but when
overexpressed with pBCins-258 there was a decrease in tran-
scriptional activity, similar to that seen with the pGL-LUC200
construct (Fig. 3A). To determine if the negative e¡ect Pax4
was having on the human insulin gene promoter was speci¢c,
another member of the Pax gene family, Pax6, the one most
closely related to Pax4, was investigated. Unlike Pax4, Pax6
had no signi¢cant e¡ect on transcriptional activity of the
pBCins-258 construct (Fig. 3B). Pax4 binding to the insulin
gene promoter was then examined by EMSA, using nuclear
extracts from BHK cells overexpressing FLAG-tagged PAX4
constructs. Two probes were used, C2 which corresponded to
sequences from 3238 to 3262 and DH1 which corresponded
to sequences from 3238 to 3275 (Fig. 4A). PAX4 was shown
to bind to both probes. Binding was inhibited by an anti-
FLAG antibody, but not by preimmune serum con¢rming
the speci¢city of the EMSA assay. We next investigated the
e¡ect of Pax4 on a series of deletion constructs corresponding
to sequences within the human IAPP promoter [13]. Pax4
exhibited a strong repressive e¡ect on the constructs contain-
ing sequences 32798 to +450, 3477 to +450, 3391 to +450,
3222 to +450, and 3138 to +450 (Fig. 5). There was no e¡ect
on the control pTKCAT plasmid. These results indicated that
PAX4 was repressing the activity of the IAPP promoter
through a site located downstream of 3138.
The repressive activity of Pax4 was further investigated by
using deletions of Pax4 fused to the DNA-binding domain of
GAL4 (amino acids 1^147) in the pSG424 vector. The GAL-
Pax4 constructs were co-transfected into the cell lines MIN6
and COS-7 together with the reporter plasmid pGAL4TK-
CAT, which contains ¢ve copies of the GAL4-binding site
upstream of the CAT reporter gene. The results showed that
full-length Pax4 (amino acids 2^349) exhibited a strong re-
pressive e¡ect in both cell types (Fig. 6). This repressive e¡ect
was also seen with constructs containing amino acids 2^230
and 231^349 as well with amino acids 131^349. This suggested
that two regions located at the NH2-terminus and the COOH-
terminus contained repressor activity. The control VP16 con-
struct exhibited positive activity in both cell types under sim-
ilar conditions.
4. Discussion
In this study we show that Pax4 acts as a transcriptional
repressor of the human insulin and IAPP promoters. The
repressive e¡ect was mapped to within the region 3229 to
3258 of the human insulin promoter. EMSA analysis further
showed that PAX4 could bind to the C2 element [14] located
within this region at 3244 to 3253. This element contains a
sequence that is also present in a related element of the rat
insulin I promoter that is known to bind Pax6 [15]. The con-
sensus binding sequence for Pax4 has yet to be characterised,
but based on the similarity in DNA-binding sites for other
members of the pax gene family [16,17] it is likely to be similar
to PAX6. In fact Pax4 has recently been shown to bind sim-
ilar DNA-binding sites in vitro as the Pax6 protein [18]. Our
data support the view that the negative Pax4-binding site is
located within the C2 element of the human insulin promoter.
The binding site within the human IAPP promoter remains to
be mapped. However, the results of Pax4 on the IAPP pro-
moter suggest that Pax4 may be having an e¡ect by binding to
the promoter downstream of 3138. Interestingly, a negative
element has been identi¢ed in the IAPP promoter located
between 3111 and 3102 [13]. Based on the consensus binding
Fig. 5. E¡ect of Pax4 on human IAPP gene promoter/CAT con-
structs. A: MIN6 cells were co-transfected with pTKCAT and
Pax4; with pTAC-138 and Pax4; with pTAC-222 and Pax4; with
pTAC-391 and Pax4; with pTAC-477 and Pax4; or with pTAC-
2798 and Pax4, as indicated. CAT activity is de¢ned as relative
CAT activity where activity is normalised against protein concentra-
tion. The data are representative of three separate experiments and
show the mean þ S.D. of four separate determinants.
Fig. 6. The transcriptional activation properties of Pax4. MIN6 cells (A) or COS-7 cells (B) were co-transfected with the reporter plasmid
pGAL4TKCAT and pSG424 (Gal4); with pGAL4TKCAT and Gal-VP16 (VP16); or with pGAL4TKCAT and the indicated Gal-Pax4 chimae-
ric constructs. CAT activity is de¢ned as relative CAT activity where activity is normalised against protein concentration. The data are repre-
sentative of three separate experiments and show the mean þ S.D. of four separate determinants.
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site for pax gene family members and particularly Pax6, this
element could also act as a possible binding site for Pax4.
Several other member of the pax gene family act as tran-
scriptional repressors. Pax2, Pax5 and Pax8 have repressive
domains that have been mapped to the COOH-terminus [19].
Pax3 also exhibits repression properties, due to a repression
domain located in the ¢rst 90 NH2-terminal amino acids [20].
In the case of Pax4 at least two regions located within the
NH2- and COOH-termini contain sequences that can act as
transcriptional repressors when fused to a heterologous tran-
scription factor. The fact that Pax4c, which lacks the 3224 to
3349 sequences at the COOH-terminus, acts as a transcrip-
tional repressor suggests that the two repressor domains can
act independently. Recently, a study demonstrated that the
COOH-terminal region of Pax4 caused weak activation of
the GAL4 reporter in 293 cells, 40% less than Pax6 [18].
Pax6 has a potent transactivation domain and no repression
domain located in its COOH-terminus, however both the
paired domain and homeodomain can exhibit some negative
e¡ects on transactivation function [21].
We isolated two Pax4 cDNAs from the rat insulinoma li-
brary. The larger form was similar to the full-length rat Pax4,
while the shorter form, which lacked 117 amino acids at the
COOH-terminus, was similar to the rat Pax4c [22]. There are
two other rat Pax4 isoforms, Pax4b and Pax4d, which did not
appear in any of the clones isolated from the rat cDNA li-
brary. This suggests that these isoforms may be expressed at
low levels in rat L-cells. Northern blot analysis of RNA from
the rat L-cell line BRIN D-11 [23] showed the presence of one
major transcript and additional smaller transcripts (data not
shown). Pax8 also has multiple isoforms that arise from alter-
native splicing of a primary transcript [24]. These Pax8 iso-
forms have di¡erent transactivating properties. In the case of
Pax4, the Pax4 and Pax4c isoforms both exhibit strong repres-
sive activity while co-expression of the two isoforms failed
(data not shown) to demonstrate any regulatory (such as
dominant negative) e¡ect of one isoform on the other.
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